IL13 and asthma: ,3 Recently, various biologics have been developed to target specific components of the Th2 response in severe asthma, with well-known examples including Omalizumab, which targets IgE; Mepolizumab and Reslizumab, which target IL-5; Benralizumab, which targets the IL-5 receptor; and Dupilumab, which inhibits IL-4 and IL-13.4